ImmunityBio, Inc. (IBRX) analyst actions
Rating and price-target actions on IBRX in the public-source dataset. Wires and filings carry few rating actions, so this list is sparse by nature — the hub's by-event-type table holds the measured analyst base rates. Back to the IBRX overview →
7 measured IBRX analyst action events.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against ImmunityBio, Inc. (IBRX) And Encourages Stockholders to Reach Out | Press release | +0.59% | +2.61% | |
| Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against ImmunityBio, Inc. (IBRX) And Encourages Shareholders to Reach Out | Press release | +1.26% | -2.87% | |
| Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against ImmunityBio, Inc. (IBRX) And Encourages Shareholders to Reach Out | Press release | +0.19% | +3.33% | |
| Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against ImmunityBio, Inc. (IBRX) And Encourages Stockholders to Reach Out | Press release | -0.58% | -0.74% | |
| Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against ImmunityBio, Inc. (IBRX) And Encourages Shareholders to Reach Out | Press release | — | +0.00% | |
| Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against ImmunityBio, Inc. (IBRX) And Encourages Stockholders to Reach Out | Press release | -0.44% | -1.41% | |
| ImmunityBio Announces Full Accrual of First Two Phases of Cancer Vaccine Trial in Participants with Lynch Syndrome and Initiation of Randomized Controlled Phase of the Trial | Press release | -1.04% | -2.30% |
Keep exploring
More IBRX: earnings → · SEC filings → · IBRX overview →